ArticleThe Laryngoscope2026
Lipofuscin: The Missing Link in the Worsening of Obstructive Sleep Apnea.
Article in The Laryngoscope, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThere is a lack of evidence linking oxidative stress to muscle dysfunction and the worsening of obstructive sleep apnea (OSA). Lipofuscin is a permanent intracellular deposit that accumulates with aging or oxidative stress. Its increase in skeletal muscles may lead to limitations in muscle function, such as weakness and fatigue. We aim to investigate whether lipofuscin deposits in the upper airway muscles of patients with severe OSA are increased compared to those in patients with primary snoring or very mild OSA.
methodsWe studied pharyngeal framework muscle tissue samples from non-obese adults, with one group having severe OSA and another having primary snoring or very mild OSA (snorer group). Lipofuscin was identified by analyzing staining patterns from Sudan Black B and fluorescence microscopy. We compared lipofuscin levels and distribution in the muscle fibers between the groups.
resultsDespite presenting similar age and body mass index, patients with severe OSA exhibited markedly larger and more concentrated deposits of lipofuscin in the upper airway muscles, particularly along the borders of the muscle fascicles, compared to the snorer group.
conclusionCompared to primary snorers, patients with severe OSA accumulate lipofuscin in their pharyngeal muscles. Our findings may provide novel insight into the role of lipofuscin as both a marker and a cause of the aggravation of OSA, in light of a possible lipofuscin-induced progressive myopathy. LEVEL OF EVIDENCE: 3:
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.